Evonik’s Self Driving Labs platform wins CPHI award

Key highlights
  • The platform won the 2026 CPHI Pharma Award in the Digital Transformation category for API development.
  • In a Grignard reaction use case, throughput rose from about two manually controlled experiments to as many as 100 autonomous experiments per day.
  • A chromatographic separation developed with Agilent was completed autonomously overnight, compared with a typical week of expert-led experimentation.
  • The platform combines Bayesian optimization, automated lab equipment, 3D-printed reactors and Evonik’s AIChemBuddy interface.

Platform and award

Evonik’s Self Driving Labs combines artificial intelligence and automated laboratory equipment to plan, run and evaluate experiments for pharmaceutical process development. The platform won the 2026 CPHI Pharma Award in the Digital Transformation category for its application in active pharmaceutical ingredient (API) development.

Reported results

In an industrial Grignard reaction use case, experimental throughput increased from around two manually controlled experiments to as many as 100 autonomous experiments per day. In a chromatographic separation developed with Agilent, a task usually requiring a week of expert-led experimentation was completed autonomously overnight, with equal or better performance.

Technology and development

The platform uses Bayesian optimization to learn from experimental results and propose subsequent conditions within a predefined, safety-assessed operating window. Experiments can run in a closed loop with minimal supervision, or staff can perform them while the algorithm guides the next steps. Evonik’s AIChemBuddy interface lets researchers explore data, build models and receive experiment proposals.

Some platform capabilities trace back to the 3D-PROCESS consortium project, which developed digitally designed, 3D-printed stainless-steel flow reactors. Their internal geometries can be tailored to specific chemistries to control exothermic reactions, reduce side products and use less solvent.

Flexible use

Evonik says the system is being extended across its global Health Care organization and can be applied in new development or to optimize existing products within regulatory frameworks. Customers can use selected components rather than full autonomous operation, depending on project needs.

Source: Evonik

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

2 September 2025
Evonik Launches Program for New Market Growth

The program targets emerging markets, focusing on circular packaging, plastics recycling, and aerospace, leveraging Evonik's expertise for innovative solutions and growth opportunities.